Cite
HARVARD Citation
Kristeleit, R. et al. (2019). Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. International journal of gynecological cancer. 29 (9), p. . [Online].